hrcak mascot   Srce   HID

Pregledni rad

MOLECULAR BASIS OF BREAST CANCER RELATED TO BRCA 1 AND BRCA2 GENES: CHARACTERISTICS AND TARGETING THERAPY

SONJA LEVANAT
Mirela LEVAČIĆ CVOK

Puni tekst: hrvatski, pdf (105 KB) str. 34-37 preuzimanja: 1.585* citiraj
APA 6th Edition
LEVANAT, S. i LEVAČIĆ CVOK, M. (2010). MOLEKULARNA OSNOVA RAKA DOJKE VEZANA UZ GENE BRCA1 I BRCA2: KARAKTERISTIKE I CILJANA TERAPIJA. Liječnički vjesnik, 132 (1-2), 34-37. Preuzeto s https://hrcak.srce.hr/63558
MLA 8th Edition
LEVANAT, SONJA i Mirela LEVAČIĆ CVOK. "MOLEKULARNA OSNOVA RAKA DOJKE VEZANA UZ GENE BRCA1 I BRCA2: KARAKTERISTIKE I CILJANA TERAPIJA." Liječnički vjesnik, vol. 132, br. 1-2, 2010, str. 34-37. https://hrcak.srce.hr/63558. Citirano 16.12.2019.
Chicago 17th Edition
LEVANAT, SONJA i Mirela LEVAČIĆ CVOK. "MOLEKULARNA OSNOVA RAKA DOJKE VEZANA UZ GENE BRCA1 I BRCA2: KARAKTERISTIKE I CILJANA TERAPIJA." Liječnički vjesnik 132, br. 1-2 (2010): 34-37. https://hrcak.srce.hr/63558
Harvard
LEVANAT, S., i LEVAČIĆ CVOK, M. (2010). 'MOLEKULARNA OSNOVA RAKA DOJKE VEZANA UZ GENE BRCA1 I BRCA2: KARAKTERISTIKE I CILJANA TERAPIJA', Liječnički vjesnik, 132(1-2), str. 34-37. Preuzeto s: https://hrcak.srce.hr/63558 (Datum pristupa: 16.12.2019.)
Vancouver
LEVANAT S, LEVAČIĆ CVOK M. MOLEKULARNA OSNOVA RAKA DOJKE VEZANA UZ GENE BRCA1 I BRCA2: KARAKTERISTIKE I CILJANA TERAPIJA. Liječnički vjesnik [Internet]. 2010 [pristupljeno 16.12.2019.];132(1-2):34-37. Dostupno na: https://hrcak.srce.hr/63558
IEEE
S. LEVANAT i M. LEVAČIĆ CVOK, "MOLEKULARNA OSNOVA RAKA DOJKE VEZANA UZ GENE BRCA1 I BRCA2: KARAKTERISTIKE I CILJANA TERAPIJA", Liječnički vjesnik, vol.132, br. 1-2, str. 34-37, 2010. [Online]. Dostupno na: https://hrcak.srce.hr/63558. [Citirano: 16.12.2019.]

Sažetak
Breast cancer is one of the most frequent tumors in women, and BRCA1 and BRCA2 genes play a major role in the hereditary susceptibility for this disease. Until the age of 70 women carrying a mutation in BRCA1 or BRCA2 gene have a 45–85% probability of developing breast cancer, and 11–62% probability of developing ovarian cancer. Mutation carrier’s tumors contain nonfunctional BRCA1 or BRCA2 genes, which in healthy cells are involved in DNA repair. These tumors show an increased sensitivity to DNA damaging chemical agents and to PARP (poly(adenosine diphosphate-ribose) polymerase1) inhibitors. New targeted therapies already in use are directed toward tumors of mutation carriers. Successful treatment is most likely to be achieved through cooperation of a pathologist, oncologist and a genetic laboratory performing BRCA genes mutation screening.

Ključne riječi
Breast neoplasms – genetics, pathology, drug therapy; Genes, BRCA1; Genes, BRCA2; Mutation – genetics; Antineoplastic agents – pharmacology

Hrčak ID: 63558

URI
https://hrcak.srce.hr/63558

[hrvatski]

Posjeta: 2.134 *